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Glyoxalase I Is Differentially Expressed in Cutaneous
Neoplasms and Contributes to the Progression of
Squamous Cell Carcinoma
Xiao-Yan Zou1,7, Dong Ding2,7, Na Zhan3, Xiao-Ming Liu4, Cheng Pan5 and Yu-Min Xia6
Glyoxalase I (GLO1) is a methylglyoxal detoxification enzyme being implicated in the progression of multiple
malignancies. However, currently, the role of GLO1 in human nonmelanoma skin tumors remains unclear. To
explore the expression of GLO1 in cutaneous neoplasms and its role in the pathogenesis of skin cancers, we
determined the GLO1 expression in multiple subtypes of cutaneous neoplasms and cell lines harboring different
tumorigenicity. Also, the GLO1 siRNA transfection was performed in squamous cell carcinoma (SCC)-13 cells or
SCC in the xenograft model. The results show that GLO1 was overexpressed by SCC, basal cell carcinoma, and
verrucous carcinoma but weakly expressed by several benign neoplasms. Human papilloma virus 16 E6/E7–
transfected keratinocytes expressed more GLO1 than did normal keratinocytes, although both of them had lower
levels of GLO1 than SCC-13 cells. Moreover, the knockdown of GLO1 by siRNA was related to enhanced
apoptosis of SCC-13 cells in the presence of tumor necrosis factor-related apoptosis-inducing ligand and
inhibited cell invasion and migration, which was mirrored by the suppressed growth of SCC xenografts in mice.
Finally, the GLO1 regulation of SCC-13 cells might be relevant to methylglyoxal-induced p53 translocation.
Therefore, GLO1 is prevailingly expressed in cutaneous neoplasms of higher malignancy and contributes to the
progression of SCC.
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INTRODUCTION
Glyoxalase I (GLO1) is an enzyme that catalyzes the thiohe-
miacetal (composed of methylglyoxal and glutathione) into
S-lactoylglutathione. This catalysis detoxifies the accumulated
methylglyoxal, a by-product of normal biochemistry,
but highly toxic to cellular proteins and nucleic acids
(Masterjohn et al., 2013). The detoxification of methyl-
glyoxal may further suppress the formation of argpyrimidine
in cell nuclei (Nakadate et al., 2009b). As an end product of
methylglyoxal-mediated protein modification, argpyrimidine
exerts cellular effects through interaction with the receptor for
advanced glycation end products, which subsequently
activates multiple inflammatory responses (Kim et al., 2012).
The augmented process of methylglyoxal detoxification
correlates with a decrease in cell apoptosis that is normally
triggered as self-regulation of proliferation and the resistance
to anti-tumor drugs that kill tumor cells through enhancing
methylglyoxal production (Thornalley and Rabbani, 2011).
Moreover, GLO1 contributes to the regulation of tumor
necrosis factor–induced NF-kB–dependent reporter gene
expression (de Hemptinne et al., 2009), which consequently
controls cell proliferation, angiogenesis, tumorigenesis, and
tumor invasion (Jin et al., 2012).
Clinical studies showed that elevated expression of GLO1 is
significantly associated with local invasion, lymph node
metastasis, pathological stage of gastric cancer (Cheng et al.,
2012), and high tumor grade of breast cancer (Fonseca-
Sa´nchez et al., 2012), suggesting a role of GLO1 in tumor
growth and progression. GLO1 was also found to express more
in pancreatic cancers as compared with related noncancerous
tissues (Wang et al., 2012). Greater amplification of GLO1
gene was identified more commonly in samples from breast,
sarcoma, non-small cell lung, bladder, renal, and gastric
cancers but rarely in colon cancers and gliomas (Santarius
et al., 2010). Using the cell lines, GLO1 was proven to be
highly expressed by erythroleukemia, Burkitt’s lymphoma, liver
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cancer, colon carcinoma, T-cell lymphoma, and histiocytic
lymphoma (Castro et al., 1990). Furthermore, the GLO1 is
overexpressed in human malignant melanoma; the siRNA
interference targeting the GLO1 expression sensitizes
metastatic melanoma cells toward the antiproliferative,
apoptogenic, and oxidative stress–inducing activity of exogen-
ous methylglyoxal (Bair et al., 2010). These reported findings
strongly indicate that GLO1 is associated with the
development and prognosis of various tumors but differentially.
Recently, targeting the glyoxalase pathway is being
regarded as a strategy to reduce the resistance of cancers to
chemotherapy drugs (Sakamoto et al., 2000; Thornalley and
Rabbani, 2011), to enhance the efficacy of tumor-killing
agents (Taniguchi et al., 2012), and to explore anti-tumoral
compounds with higher specificity but lower toxicity (Santel
et al., 2008). However, to date, the role of GLO1 in
nonmelanoma cancers and benign proliferative diseases of
the skin is poorly explored. This study was designed to
investigate the expression of GLO1 in cutaneous neoplasms
and its relation to the fate of keratinocyte-derived skin cancers.
RESULTS
GLO1 is highly expressed in cutaneous malignancies
We detected the GLO1 expression in multiple human skin
neoplasms and normal tissues. Immunohistochemical staining
showed strong expression of GLO1 in the lesional tissues of
squamous cell carcinoma (SCC; n¼10), basal cell carcinoma
(BCC; n¼ 7), or verrucous carcinoma (n¼4; Figure 1a–c).
However, the samples of Bowenoid papulosis (n¼ 8), sebor-
rheic keratosis (n¼7), trichoepithelioma (n¼9), epidermal
nevus (n¼ 7), and anogenital warts (n¼ 15) revealed only
slight GLO1 staining, which differed from the normal skins
(n¼ 10) but not notably (Figure 1d–i). A cytoplasmic pattern of
GLO1 expression was seen in all positive cases, but strong
nuclear staining of GLO1 was also found in BCC samples. In
normal skins, basal cells were specifically stained at a low
level. The patterns of GLO1 staining were stable within each
subtype of skin samples but with slightly altered strength in
individuals. Western blotting analysis confirmed elevated
GLO1 expression in fresh tissues of SCC, BCC, and verrucous
carcinoma as compared with the benign tumors or normal
controls (Figure 1j), which was consistently reflected by real-
time reverse-transcriptase–PCR (qRT-PCR) (Figure 1k). There
were no statistical differences between the malignant samples
or between the benign samples in protein or mRNA levels of
GLO1 (P40.05). Similarly, the mRNA expression of nuclear
factor erythroid 2–related factor 2 (Nrf2) was higher in the skin
malignancies but lower in normal skin, as compared with the
benign neoplasms (Figure 1l).
GLO1 is overexpressed by SCC-13 cells in vitro
Both SCC-13 (human SCC cell line) and HaCaT (human
keratinocytes) cells were detected for GLO1 expression. By
immunofluorescence, the elevated GLO1 expression was seen
with human papilloma virus (HPV) type 16 E6/E7–transfected
HaCaT cells as compared with normal HaCaT cells, which
was even greater in SCC-13 cells (Figure 2a). Quantitative
results were obtained from flow cytometry (FCM), showing the
strongest expression of GLO1 in SCC-13 cells and the weakest
in normal keratinocytes (Figure 2b). Cells were harvested for
the extraction of protein or mRNA, which showed the highest
levels of GLO1 and Nrf2 in the SCC-13 group (Figure 2c and
d). Moreover, the intracellular methylglyoxal and argpyrimi-
dine were significantly reduced in SCC-13 cells as compared
with two HaCaT cell groups, although E6/E7 transfection
induced less methylglyoxal and argpyrimidine production in
HaCaT cells (Figure 2e).
GLO1 knockdown enhances the apoptosis of SCC-13 cells
To study the role of GLO1 in downregulation of cell cycle,
SCC-13 cells were transfected with GLO1 siRNA or control
siRNA. Three days later, immunofluorescence, FCM, and
western blotting were performed, verifying the success of
siRNA transfection (Figure 3a–c). Intracellular methylglyoxal
and argpyrimidine also increased upon GLO1 siRNA transfec-
tion (data not shown). The GLO1 siRNA–transfected cells
displayed more apoptotic nuclei in the TUNEL assay
(Figure 3d, top panel). Moreover, GLO1 siRNA transfection
augmented the apoptotic response of cells to the 24-h
stimulation of tumor necrosis factor–related apoptosis-indu-
cing ligand (TRAIL) (Figure 3d, bottom panel). The protease
(caspase-3,7) activity assay provided quantitative results
(Figure 1e), which were similar to the TUNEL assay. Consis-
tently, the normal and control siRNA–treated cells proliferated
more quickly compared with the GLO1 siRNA–treated cells,
and the TRAIL stimulation sensitized the inhibition of cell
proliferation by GLO1 siRNA transfection (Figure 3f). The
protein expression of Bcl-2, Bcl-xL, survivin, and X-linked
inhibitor of apoptosis protein all decreased after GLO1 siRNA
transfection (Figure 3g and h).
Methylglyoxal and argpyrimidine modulate cancer-related
pathways
As two important compounds regulated by GLO1, methyl-
glyoxal and argpyrimidine were studied for the mechanisms
in GLO1-related tumorigenicity. We found that the addition
of exogenous methylglyoxal altered the expression pattern of
p53 protein by SCC-13 cells. In western blotting, the
methylglyoxal treatment did not affect the total p53 level
but increased the p21 expression (Figure 4a), which was even
confirmed by mRNA analysis (data not shown). However,
immunofluorescence and FCM verified the accumulation of
p53 protein in nuclear areas and cellular membrane upon
methylglyoxal stimulation (Figure 4b and c). Moreover, the
addition of methylglyoxal or argpyrimidine inhibited NF-kB
activation (Figure 4d and e). Furthermore, the GLO1 siRNA
transfection suppressed the NF-kB pathway particularly under
TRAIL stimulation (Figure 4f and g), whereas the control
siRNA (higher cellular GLO1) detained the effect of methyl-
glyoxal on both cell cycle and p53 expression (Supple-
mentary Figure S1 online).
Both migration and invasion of SCC-13 cells weaken as GLO1
expression is suppressed
The effect of GLO1 on the progression of SCC was eva-
luated in vitro. In the wound-healing assay, the GLO1
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siRNA–transfected SCC-13 cells migrated more slowly than
did normal or control siRNA–transfected cells (Figure 5a).
Also, the Boyden chamber assay showed fewer SCC-13 cells
migrating through the millicell chambers when GLO1 siRNA,
but not control siRNA, was transfected into the cells
(Figure 5b). Similar differences between GLO1 siRNA– or
control siRNA–transfected cells were also observed in the
invasion assay (Figure 5c). However, there was no difference
between normal cells and control siRNA–treated cells in either
migration or invasion assay (P40.05).
GLO1 siRNA transfection ameliorates SCC xenografts in mice
We assessed the effect of GLO1 suppression on SCC implan-
ted in severe combined immunodeficiency mice. Both qRT-
PCR and western blotting confirmed the knockdown of GLO1
expression by GLO1 siRNA transfection (Supplementary
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Figure 1. Glyoxalase I (GLO1) expression in tissue samples. By immunohistochemistry, strong positivity was shown in squamous cell carcinoma (SCC) (a), basal
cell carcinoma (BCC) (b), and verrucous carcinoma (c), whereas weak staining was seen in Bowenoid papulosis (d), seborrheic keratosis (e), trichoepithelioma (f),
epidermal nevus (g), and anogenital wart (h). (i) Slight basal cell staining was exhibited in normal epidermis. (j) Western blotting was performed on all samples,
revealing higher GLO1 in three malignancies as compared with the others. (k, l) The mRNA levels of GLO1 (k) and nuclear factor erythroid 2–related factor 2
(Nrf2) (l) were also higher in the three malignancies. There were no differences in both GLO1 and Nrf2 expression between the malignancies or between the
benign neoplasms (P40.05). Representative images are shown. Bar¼ 50mm. *Po0.05; **Po0.01.
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Figure S2 online). The GLO1 siRNA–transfected mice had
smaller tumors as compared with those treated with control
siRNA or phosphate-buffered saline (PBS) since 4 weeks after
SCC cell inoculation (Figure 6a and b). In survival analysis,
GLO1 siRNA–transfected mice lived longer compared with
the control groups (Figure 6c). The observation for metastasis
showed that all mice at death had visible tumors in distant
organs (lungs, livers, or mesenteries). However, at early stage
(6 weeks after inoculation), the GLO1 siRNA–transfected
group (1/8) had lower ratio of adjacent metastasis (within
2 cm around original tumors) compared with the control
siRNA (4/8) or PBS (5/8) groups. There was no significant
difference between the latter two groups in tumor volume,
mouse survival, or adjacent metastasis (P40.05).
DISCUSSION
In the present study, we showed that GLO1 is selectively
overexpressed in SCC, BCC, and verrucous carcinoma tissues
as well as in the immortal SCC cell line. The in vitro inhibition
of GLO1 expression not only increases the apoptosis of SCC
cells, which may be augmented upon TRAIL stimulation, but
also suppresses the migration and invasion of SCC cells. The
favorable role of GLO1 in tumoricity of SCC cells involves the
enhancement of p53–p21 axis and inhibition of NF-kB
signaling by methylglyoxal or argpyrimidine. Moreover,
in vivo inhibition of GLO1 expression supportively causes
tempered progression of SCC xenografts in the mouse model.
Our results convincingly demonstrate the pivotal role of GLO1
in the regulation of tumor cell cycle and malignant behaviors
of cutaneous neoplasms.
SCC and BCC are the two most common subtypes of skin
malignancies in white or Asian populations (Koh et al., 2003;
Lomas et al., 2012). SCC differs from BCC not only in the
origination of affected skin cells but also in possessing more
aggressive growth and higher metastatic potential. As well-
differentiated SCC, verrucous carcinoma is a borderline lesion
with locally aggressive invasion but rarely presents with
distant metastasis (del Pino et al., 2012). Our results
demonstrate that GLO1 is highly expressed in SCC, BCC,
and verrucous carcinoma, and lower expression exists in
benign skin neoplasms. Moreover, the staining pattern is
differential between SCC and BCC. SCC samples clearly
display a pattern of cytoplasmic staining, whereas both
cytoplasmic and nuclear staining patterns are seen in BCC.
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Figure 2. Glyoxalase I (GLO1) expression in squamous cell carcinoma (SCC)-13 and HaCaT cells. (a) Immunofluorescence showed the strongest GLO1
expression (green) in SCC-13 cells, followed by E6/E7-transfected and normal HaCaT cells in order. (b) Flow cytometry confirmed elevated GLO1 expression in
SCC-13 cells and E6/E7-transfected HaCaT cells as compared with normal HaCaT cells. (c) Western blotting revealed the highest level of GLO1 in SCC-13 cells.
(d) Consistently, GLO1 and nuclear factor erythroid 2–related factor 2 (Nrf2) mRNA analysis exhibited the highest level in SCC-13 cells and the lowest in normal
HaCaT cells, respectively. (e) The intracellular methylglyoxal and argpyrimidine were significantly reduced in SCC-13 cells as compared with the controls. Data
were obtained from three to five independent experiments. Representative images are shown. Bar¼ 5mm. *Po0.05; **Po0.01. DAPI, 40,6-diamidino-2-
phenylindole; PE, phycoerythrin.
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These findings revealed that GLO1 expression correlates
closely to the degree of malignancy of skin tumors and even
reflects the cellular origin of cancers. Actually, GLO1 has both
diffuse cytoplasmic and nuclear patterns in staining various
cells (Nakadate et al., 2009a), and one protein may
predominantly localize in either the cytoplasm or the nuclei
of tumor cells, depending on their origins or even their grades
(Rothberg et al., 2008; Skagias et al., 2009). Therefore, the
difference in GLO1 expression patterns may help distinguish
SCC from BCC in diagnosis.
Skin SCC has been strongly suggested to be related to HPV
16 infection (Croci-Torti et al., 2014). The expression of E6/E7
oncogenes contributes to HPV 16–induced epidermal dyspla-
sia, which may eventually trigger oncogenic conversion (Yu
et al., 2010). In the present study, HPV 16 E6/E7 transfection
enhanced GLO1 expression in HaCaT cells, indicating an
involvement of cellular GLO1 synthesis in the malignant
transformation of keratinocytes after harboring oncogenes.
The SCC-13 cell line, which is conferred with intact
biological features of SCC cells, produces more GLO1
compared with E6/E7-transfected HaCaT cells, providing
supportive evidence that an elevation in GLO1 expression is
specific to the malignancy degree of keratinocyte-derived
tumors. However, we found no significant difference in
GLO1 expression between SCC and its low-grade variant,
verrucous carcinoma. This may be related to the limited
numbers of tissue samples in the present study and deserves
further investigation. Nrf2 is a transcription factor involved in
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Figure 3. The effects of glyoxalase I (GLO1) siRNA transfection on squamous cell carcinoma (SCC)-13 cells. Immunofluorescence (a), flow cytometry (b), and
western blotting (c) verified reduced GLO1 expression by SCC-13 cells upon GLO1 siRNA transfection. In the TUNEL (green) detection (d) and caspase activity
assay (e), the GLO1 siRNA–transfected cells showed increased apoptosis as compared with the controls. Under the stimulation of tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL) (20 ng ml1, 24 hours), GLO1 siRNA transfection augmented the increase of cell apoptosis. (f) The proliferation assay showed
results consistent with apoptosis evaluation. (g, h) Western blotting analysis showed that GLO1 siRNA transfection lowered the cellular expression of cancer-
related proteins. Data were obtained from three independent experiments. Representative images are shown. Bars¼ 5mm (a) or 20mm (d). *Po0.05; **Po0.01.
DAPI, 40,6-diamidino-2-phenylindole; PBS, phosphate-buffered saline; PE, phycoerythrin; XIAP, X-linked inhibitor of apoptosis protein.
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cancer cell proliferation (Leinonen et al., 2014) and has been
suggested in the transcriptional control of GLO1 (Xue et al.,
2012). Our results demonstrate elevated mRNA expression of
Nrf2 in both skin malignancies and E6/E7-transfected keratino-
cytes, and thus indicate a possible mutual pathway under-
lining the increase in cellular GLO1 during tumorigenicity.
One of the most important characteristics that differentiate
malignant tumors from benign ones is accelerated prolifera-
tion in the former. In SCC, the cellular proliferation can be
inhibited by the apoptotic effect induced by TRAIL (Rachow
et al., 2013). We applied siRNA transfection to silence GLO1
expression in SCC-13 cells and found decreased cell
proliferation in the absence of TRAIL and an augmentation
of such decrease in the presence of TRAIL. Moreover, the
inhibition of cell proliferation by GLO1 silence is related to
the downregulation of protein expression of apoptosis
inhibitors, including Bcl-2, Bcl-xL, survivin, and X-linked
inhibitor of apoptosis protein, which has been similarly
reported in other cancer cells (Taniguchi et al., 2012).
Hence, the overexpression of GLO1 may be partially
responsible for the remarkable growth and proliferation
of SCC.
The GLO1 detoxification not only decreases cellular
methylglyoxal but also subsequently suppresses the formation
of argpyrimidine. Recently, methylglyoxal was also found to
promote nuclear translocation of p53, although not altering
p53 total protein in hepatocarcinoma cells (Loarca et al.,
2013). In the present study, we not only confirmed such
similar phenomenon in SCC cells but also demonstrated that
p21 expression is enhanced by methylglyoxal stimulation. The
activation of p21 signaling is tightly controlled by p53 in the
nuclei (Jiang et al., 2014), and the nuclear accumulation of
p53 may explain the increase in p21 expression. The
mechanism for methylglyoxal regulation of p53 migrating
from cytoplasm needs to be elucidated in further studies.
Cytoplasmic argpyrimidine fluctuates consistently with the
alteration of methylglyoxal (Kim et al., 2012). Our results
show that the NF-kB activation in SCC-13 cells can be inhi-
bited by argpyrimidine, indicating the possible mechanism
that GLO1 contributes to tumoricity by intermediately
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methylglyoxal stimulation did not alter the total p53 level but enhanced p21 expression. (b) Immunofluorescence revealed more p53 expression (red) in nuclear
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(d) Methylglyoxal inhibited the expression of nuclear p65 and phosphorylated IkB, and enhanced the unphosphorylated IkB level. (e) Argpyrimidine exerted effect
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triggering NF-kB-regulated genes, which consequently
regulate cancer-related pathways (Antognellia et al., 2013;
Ferris and Grandis, 2007). Considering the fact that p53 as a
transcription factor can either directly interact with NF-kB
subunits or affect NF-kB target genes (Hoesel and Schmid,
2013), we believe that the methylglyoxal- and argpyrimidine-
mediated cooperativity between p53–p21 axis and NF-kB
signaling may be instrumental in the GLO1 modulation of
tumorigenicity.
Furthermore, the effects of GLO1 on the migration and
invasion of SCC were studied by performing in vitro assays.
The results verify significant attenuation of SCC cell migration
and invasion as GLO1 expression was knocked down by
siRNA transfection. Clinical studies previously suggested
positive correlation between the overexpression of GLO1
and gastric wall invasion as well as lymph node metastasis
of gastric cancer (Cheng et al., 2012). Therefore, our findings
add to this conclusion by providing in vitro evidence that
GLO1 takes part in the modulation of cancer cells not only by
enhancing cell proliferation but also by altering cell
phenotype. Moreover, the inhibition of SCC progression in
the xenograft model by GLO1 siRNA transfection supports the
assumption that targeting GLO1 expression could be
therapeutic approaches for SCC.
Collectively, this study revealed the differential expression
of GLO1 in skin malignant and benign neoplasms, which may
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control siRNA. Each sample was triplicated, and data were obtained from three independent experiments. Representative images are shown. *Po0.05; **Po0.01.
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Figure 6. Effect of glyoxalase I (GLO1) siRNA transfection on mice with xenografts. (a) During the period of 4–14 weeks since SCC-13 cell implantation, the mice
in the GLO1 siRNA group had lower tumor volumes compared with the others. There was no difference between the two controls (P40.05). (b) Representative
images of xenografts are shown, indicating inhibited tumor growth upon GLO1 siRNA transfection (narrow arrows indicating diameters), although sizes were
similar at 2 weeks. Small nodal metastases (arrowhead) around the original implant were seen in the control siRNA group. (c) In survival analysis, the GLO1
siRNA–transfected mice had longer life as compared with the controls, the latter of which had no difference from each other (P40.05). n¼8 in each group. PBS,
phosphate-buffered saline.
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help with the differential diagnosis of certain tumors and also
explain partially the aggressive behaviors of SCC. The impor-
tant role of GLO1 in modulating tumorigenicity involves the
regulation of p53–p21 axis and the NF-kB pathway by
methylglyoxal and argpyrimidine. In addition, the knockdown
of GLO1 can ameliorate the progression of SCC in vitro and
in vivo, herein indicating that GLO1 serves as a potential
target in the treatment of SCC.
MATERIALS AND METHODS
Tissues samples
The lesional specimens were obtained from outpatients who had
been diagnosed both clinically and pathologically but received
neither pharmaceutical nor physical therapy. We also collected
normal skin tissues from patients undergoing routine surgery without
cutaneous or inflammatory-mediated diseases. The samples were
formalin fixed and embedded in paraffin, whereas some fresh tissues
were surgically dissected of free subcutaneous fat before freezing at
 80 1C. The demographic data of the patients are listed in
Supplementary Table S1 online. The study was carried out under
the supervision of the research ethics committees. Written informed
patient consent was obtained before harvesting tissue samples.
Immunohistochemistry
After routine dewaxing and microwave antigen retrieval, paraffin
sections were permeabilized with 0.1% Triton-100/PBS. Sections
were blocked with dual endogenous enzyme block (DAKO, Glostrup,
Denmark), followed by incubation with 2mg ml 1 of rabbit anti-
GLO1 (Santa Cruz Biotech, Dallas, TX) at room temperature for 2 h
Next, the horseradish peroxidase–labeled polymer-conjugated goat
anti-rabbit immunoglobulin G (IgG; DAKO) was applied to sections
before the color (brown) development with 3,30-diaminobenzidine-
chromogen substrate. Finally, the sections were counterstained with
Mayer’s hematoxylin.
Cell culture, retroviral infection, and siRNA transfection
SCC-13 (Streit et al., 1999) and HaCaT cells were routinely grown in
Dulbecco’s modified eagle media with 10% fetal bovine serum.
Methylglyoxal or argpyrimidine (1 mM; from Fisher Scientific, Hudson,
NH) was added to certain wells for 48 hours in subsequent experiments.
The retroviral infection of HPV16 E6/E7 genes was performed on
HaCaT cells as described previously (Guerrini et al., 2011).
The in vitro siRNA transfection was carried out by following a
standard protocol (Chang et al., 2012). The predesigned GLO1 and
control siRNAs (Life Technologies, Carlsbad, CA; Supplementary
Table S2 online) were dissolved in lipofectamine 2000 reagent at a
ratio of 10 pmolml 1. The final concentrations of siRNAs in media
were 15 pmolml 1. Cells were used for assays 3 days after transfec-
tion. Both mRNA and protein lysates were extracted from cell cultures.
Recombinant human TRAIL/Apo2L (PeproTech, Rocky Hill, NJ) was
used at 20 ng ml 1 for the 24-h stimulation of SCC-13 cells, which
were cultured in 2% fetal bovine serum media. Cells were washed
with PBS at harvest before being processed for later experiments.
qRT-PCR
By using the PureLink RNA kit (Invitrogen, Grand Island, NY), total
RNA was extracted from fresh tissues or cell cultures. Reverse
transcription was performed with a commercial cDNA kit (Applied
Biosystems, Carlsbad, CA). qRT-PCR was carried out using the
7900HT Fast PCR System (Applied Biosystems). SYBR Green Master
Mixes (Invitrogen) was used as fluorescent dye. The sequences of
primers (Invitrogen) are listed in Supplementary Table S2 online.
Western blotting
Protein lysates were extracted using RIPA lysis buffer supplemented
with protease inhibitor cocktail (Thermo Scientific, Shanghai, China).
After electrophoresis separation, proteins were transferred onto poly-
vinylidene difluoride membranes. The rabbit primary antibodies
(Santa Cruz Biotech) were used, followed by incubation with horse-
radish peroxidase–labeled goat anti-rabbit IgG (Southern Biotech,
Birmingham, AL). The p65 protein in nuclear and cytoplasmic
fractions was detected separately by the NF-kB activation assay kit
(FIVEphoton Biochem, San Diego, CA). Signals were obtained with an
ECL kit (Thermo Scientific). All normalized intensity was quantified by
ImageJ1.61u (National Institutes of Health, Bethesda, MD).
Immunofluoresce and FCM
For immunostaining, cells grown on cover glass were fixed with 4%
paraformaldehyde solution. After blocking, cells were incubated with
rabbit anti-GLO1 IgG (or anti-p53 IgG; Santa Cruz Biotech), and then
stained with FITC (or Cy5)–labeled goat anti-rabbit IgG. In FCM, the
phycoerythrin-labeled anti-rabbit IgG was used as secondary anti-
body before detecting with an LSRII instrument (BD Biosciences, San
Jose, CA). Data were analyzed using the FlowJo7.6.1 software (Tree
Star, Ashland, OR).
Methylglyoxal and argpyrimidine assays
Intracellular methylglyoxal was measured using reversed-phase high-
performance liquid chromatography (Antognelli et al., 2013).
5-Methylquinoxaline was used as an internal standard.
Argpyrimidine was also analyzed with HCl-treated cell lysates
(Gangadhariah et al., 2010).
Detection of cell apoptosis and proliferation
The apoptotic cells were visualized using the TUNEL method (Greene
et al., 2013) and quantitatively analyzed using a CaspaTag caspase
3,7 assay kit (EMD Millipore, Billerica, MA). Cell proliferation was
determined with CellTiter 96 solution (Promega, Madison, WI).
Cell migration and invasion assays
The standard wound-healing assay (scratch assay) and the Boyden
chamber assay were performed to detect the motility ability of SCC-
13 cells (Sun et al., 2011). In the wound-healing assay, cell
monolayers were scratched with a sterile pipette tip. After removal
of detached cells, the wound gaps were monitored with a microscope
fitted with digital camera. In the Boyden chamber assay, the amount
of migration was determined on the basis of 0.1% crystal violet
positivity on the lower side as a percentage of the total in the
chamber. The invasion assay was performed similarly, but using
matrigel pre-coated membranes. The cellular migration or invasion
was determined by counting the number of cells on membranes in
four randomly selected fields under  400 microscope by an
investigator blind to the grouping. To verify that the siRNA
inhibition was a direct effect on invasion ability but not because of
a reduction in cell proliferation, we performed the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
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Murine model of SCC xenografts
Twenty-four male severe combined immunodeficiency mice aged 10
weeks were subcutaneously injected with SCC-13 cells (1 107 cells
per mouse). Two weeks later, the tumors became visible with an
average size of 2 mm. Mice were divided equally into three groups,
one of which received in vivo transfection of GLO1 siRNA (1 nmole
in 30ml PBS, complexed with 0.9% atelocollagen; Koken, Tokyo,
Japan) (Fujii et al., 2006). The other groups were treated with either
control siRNA or PBS. The transfection was repeated weekly and
lasted 4 weeks. The tumor volumes were calculated using the
geometric model of 4/3p ((aþ b)/4)3, wherein the a and b represent
the two orthogonal dimensions. Mice were monitored for survival
analysis. For the confirmation of siRNA transfection, 12 additional
mice were treated as above but killed 4 weeks after cell inoculation.
The original tumors were harvested for mRNA and protein extraction.
Animal experiments were approved by the institutional animal care
and use committee.
Statistical analysis
Data were expressed as the mean±SEM. Statistical analysis was
carried out using the STATA 10.0 software (StataCorp, College
Station, TX). Analysis of variance was used for the comparison of
more than two groups. A two-tailed t-test was used when two groups
were compared for statistical differences. Survival analysis was
performed using the Kaplan–Meier method. The differences were
considered significant at Po0.05.
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